Adecto has shut down. Chief executive Nora Mineva said the biotech had fought hard to keep going, and the company named a risk-averse funding environment as the reason it could not.
Adecto was built on a specific piece of research: the finding that the transmembrane protein ADAM8 drives both primary tumour growth and its spread, and the design of an antibody approach to inactivate the two extracellular domains responsible. Mineva co-founded the company on that work, with triple-negative breast cancer as the first intended indication, and it isolated two therapeutic lead antibodies that went into pre-clinical development.
None of that is in dispute. The company did not fail a trial. It ran out of the ability to raise the next tranche in a market that had stopped writing cheques for early-stage science.
The sector context is brutal and well documented. Fierce Biotech’s annual graveyard listed sixteen shutdowns in 2025 alone, with several more on the edge, against a backdrop its reporting described as a near standstill in industry activity. Arena BioWorks, launched in January 2024 with 500 million dollars from five billionaires, shut down less than two years later citing the adverse impact of biotech macro conditions and a rate of change that was accelerating with no clear turning point. AmplifyBio closed and laid off all 212 employees after months of exploring every investment and acquisition possibility. Industry reporting through the year described venture capital, listings and other funding sources drying up simultaneously, with pharmaceutical partners pushing risk back onto biotechs through smaller upfront payments and milestones staged along the route to approval.
The uncomfortable lesson is one that most business writing avoids because it offers nothing actionable.
Some businesses fail for reasons entirely outside the founder’s control, and no amount of execution would have changed the outcome. Adecto needed a market in which investors would fund pre-clinical oncology work on a multi-year horizon. That market existed for most of the past decade. It did not exist this year. The company’s science is the same science it was in 2023.
There is something worth saying about what that means for how we read failure generally.
The story told afterwards almost always attaches to the company. They raised too slowly. They should have partnered earlier. They did not have the right commercial leadership. Some of those criticisms are fair in individual cases, and the survivorship problem is that the companies which did exactly the same things in a kinder year are now described as well run.
The practical implication for anyone building something capital-dependent is narrow but real. The financing environment is a variable in your plan, not a background condition, and it moves far faster than any technical milestone you are working toward. A plan that requires three more raises is a plan that requires the window to be open three more times.
Mineva’s phrasing was that the company fought hard to keep going.
The antibodies exist. The timing did not.
Source: Fierce Biotech, “Adecto blames ‘risk-adverse funding environment’ for closing”
